RANBAXY LABORATORIES LIMITED 
By Gurgaon, Haryana, India, Daiichi Sankyo India Pharma Pvt. Ltd. (DSIN) and Ranbaxy Laboratories Ltd (Ranbaxy) together with the Royal Society of Chemistry (RSC) organized a symposium titled "Overcoming the Bottlenecks in Drug Discovery and Development" in Gurgaon on March 20 & 21, 2014. The two-day symposium was attended by over 400 delegates from many countries including, India, Japan, USA, UK, Singapore and featured lectures from leading researchers on four key pharmaceutical R&D themes:
- Biological hit identification
- Chemical hit identification
- Pharmaceutical research
- Chemical hit to lead optimization
With an estimated cost of discovering a new molecular entity soaring past US $1 Bn and the significant gaps in providing affordable medicines around the world, the conference took on the challenge of productivity improvement in Pharmaceutical R&D. Speakers highlighted recent advances in computational tools for lead optimization and new methodologies for chemical hit / target identification and delivery of medicines. The exhilarating journey from lead optimization to successful commercialization of the Daiichi Sankyo's recently-approved drug Edoxaban was shared as a case study.
The symposium also featured a poster session and a student poster competition. The poster entries were judged by an international panel and selected posters were invited for flash oral presentations during the conference.
On the occasion of the conference, Dr. Tsutomu Une, Chairman of Ranbaxy Laboratories Ltd. commented: "It was a wonderful experience to see academic, industry and government leaders from all over the world converge to share recent advances in drug discovery and development. It has further cemented India's position as an R&D hub for the pharma industry while more substantial collaboration among Government, academia and industries is required in India upon the global network."
Dr. Takahide Nishi, CEO of Daiichi Sankyo India Pharma Pvt. Ltd. commented: "It was a great joy for those of us who cooperated in convening this conference to provide so many people with insights into the challenges facing modern drug discovery and development. The whole event was a stimulating experience and I believe everyone profited from the lively exchange of opinions and ideas."
Dr. Alejandra Palermo, Open Innovation Manager at the Royal Society of Chemistry commented, "This drug discovery and development conference is the first such event that the Royal Society of Chemistry has delivered with industry partners in India and demonstrates our commitment to supporting healthcare research and to developing even stronger and more successful international networks to help chemical scientists across the world to share the best ideas."
"As part of the conference, we also hosted an Open Forum discussion to address how open science can spark innovation in the area of neglected diseases. This session will help shape how we expand our open science activities into other areas of healthcare research in collaboration with key partners."
"This follows two successful events that were run from Hyderabad in collaboration with the Indian Institute of Chemical Technology and an MoU with CSIR Open Source Drug Discovery to work in the area of drug discovery and drug development."
Among the leading speakers during the two day conference were Abdul Basit, University College London, UK, Ian Collins, The Institute of Cancer Research, UK, Ben Davis, Vernalis, UK, Gautam Desiraju, Indian Institute of Science, India , Ulrike Eggert, King's College London, UK, Paul Gleeson, Kasetsart University, Thailand, Anne Hersey, EMBL-European Bioinformatics Institute, UK, Andrew Leach, Liverpool John Moores University/ MedChemica Ltd, UK, Masatoshi Nagamochi, Daiichi Sankyo, Japan, William Pennie, Pfizer, US, Ashok Prasad, Delhi University, India, Kunal Roy, Jadavpur University, India, Narahari Sastry, CSIR-Indian Institute of Chemical Technology, India, Ravi Shanker, Pfizer, US and Fumiaki Yokokawa, Novartis Institute for Tropical Diseases, Singapore
Daiichi Sankyo India Pharma Private Limited (DSIN) is an organization working in the field of innovative pharmaceutical Research & Development (R&D) in India. DSIN was established in 2007 and has given a great contribution to global R&D in Daiichi Sankyo Group which has a history of more than 100 years. DSIN aim is to create first-in-class and best-in-class drugs which meet medical needs for the patients around the world. At DSIN, we keep ourselves up to date on the Research & Development technology and innovation. For more information, please visit http://www.dsin.co.in/
Ranbaxy Laboratories Limited, India's leading pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan. For more information, please visit www.ranbaxy.com
The Royal Society of Chemistry (RSC) is the world's leading chemistry community, advancing excellence in the chemical sciences. With 49,000 members and a worldwide knowledge business that spans the globe, RSC is UK's professional body for chemical scientists; a not-for-profit organisation with 170 years of history and an international vision for the future. RSC promote, support and celebrate chemistry and works to shape the future of the chemical sciences - for the benefit of science and humanity. Ranbaxy Laboratories Limited, India's leading pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan.www.ranbaxy.com
|
distributed by
|
